Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia

Yang Gao,1,2 Rónán O’Caoimh,1 Liam Healy,1 David M Kerins,3,4 Joseph Eustace,5 Gordon Guyatt,6 David Sammon,2 D William Molloy1,7

ABSTRACT

Objectives: There is growing evidence that antihypertensive agents, particularly centrally acting ACE inhibitors (CACE-Is), which cross the blood–brain barrier, are associated with a reduced rate of cognitive decline. Given this, we compared the rates of cognitive decline in clinic patients with dementia receiving CACE-Is (CACE-I) with those not currently treated with CACE-Is (NoCACE-I), and with those who started CACE-Is, during their first 6 months of treatment (NewCACE-I).

Design: Observational case–control study.

Setting: 2 university hospital memory clinics.

Participants: 817 patients diagnosed with Alzheimer’s disease, vascular or mixed dementia. Of these, 361 with valid cognitive scores were included for analysis, 85 CACE-I and 276 NoCACE-I.

Measurements: Patients were included if the baseline and end-point (standardised at 6 months apart) Standardised Mini-Mental State Examination (SMMSE) or Quick Mild Cognitive Impairment (Qmci) scores were available. Patients with comorbid depression or other dementia subtypes were excluded. The average 6-month rates of change in scores were compared between CACE-I and NoCACE-I patients.

Results: When the rate of decline was compared between groups, there was a significant difference in the median, 6-month rate of decline in Qmci scores between CACE-I (1.8 points) and NoCACE-I (2.1 points) patients (p<0.049), with similar, non-significant changes in SMMSE. Median SMMSE scores improved by 1.2 points in the first 6 months of CACE treatment (NewCACE-I), compared to a 0.8 point decline for the CACE-I (p<0.003) group and a 1 point decline for the NoCACE-I (p<0.001) group over the same period. Multivariate analysis, controlling for baseline characteristics, showed significant differences in the rates of decline, in SMMSE, between the three groups, p<0.002.

Conclusions: Cognitive scores may improve in the first 6 months after CACE-I treatment and use of CACE-Is is associated with a reduced rate of cognitive decline in patients with dementia.

ARTICLE SUMMARY

Article focus

Treatment options for dementia, including Alzheimer’s disease, remain limited. The purpose of this study was to examine the effect of centrally acting ACE inhibitors (CACE-Is) on the rate of cognitive decline in patients with dementia.

This study also examined the acute effect of CACE-Is on cognition, during the first 6 months of treatment.

Key messages

- Reduced rates of cognitive decline were seen in an unselected outpatient sample, prescribed CACE-Is, irrespective of the blood pressure readings or diagnosis of hypertension.
- The rate of decline was reduced in patients in the 6 months after starting CACE-Is, compared to those already established on them.

Strengths and limitations of this study

- This study used observational data collected in a ‘real world’ setting, where treatments, including antihypertensive agents, were administered on the basis of clinical judgement.
- The study investigated the effects of CACE-Is in an unselected clinic sample of older adults with different dementia subtypes, whose mean age approached 80 years.
- Although most patients in the database had Qmci or SMMSE recorded, large numbers lacked results at the baseline or end point, limiting the numbers that could be included in the analysis.
- Change over 6 months of treatment was analysed. Different effects may have been demonstrated over a longer period.

INTRODUCTION

As populations age worldwide, the incidence of dementia will increase. By 2040, approximately 81 million people worldwide will be affected.1 Until now, no agents have been identified that prevent, modify or reverse dementia, and available treatments for dementia are predominantly symptomatic.2 There is growing recognition of the role of cardiovascular risk factors, especially in midlife, in the conversion and progression of mild cognitive impairment (MCI)
Centrally acting ACE inhibitors in dementia

and dementia. Blood pressure (BP) control, in particular, is associated with both a reduced incidence of cognitive impairment (CI) and rate of cognitive decline. Several antihypertensive agents are associated with a lower risk of developing dementia, including calcium channel blockers (CCBs), diuretics, angiotensin receptor blockers (ARBs) and ACE inhibitors (ACE-Is). ACE-Is and ARBs affect the renin angiotensin system and may lower dementia risk, independent of their BP lowering properties. Results of clinical trials investigating the potential role of anti-hypertensives are limited and conflicting. The Perindopril Protection against Recurrent Stroke Study (PROGRESS) demonstrated that a combination of perindopril (ACE-I) and indapamide (diuretic) was associated with a significant reduction in the incidence of stroke and in cognitive decline, compared to placebo. The Systolic Hypertension in Europe (Syst-Eur) study found that the combination of enalapril (ACE-I), nitrendipine (CCB) and/or hydrochlorothiazide (diuretic) reduced the incidence of dementia by 55%, compared to placebo. Monotherapy with the ARB, candesartan, in the Study on Cognition and Prognosis in the Elderly (SCOPE) also showed modest effects. Not all studies have shown cognitive benefits with antihypertensive agents; some implicate them in the worsening of cognition. The ONTARGET and TRANSCEND trials, two parallel studies involving more than 25,000 patients, found that ACE-Is did not have any measurable effects on cognition. Although the evidence is limited, treatment with antihypertensives has been associated with reduced rates of cognitive and functional decline in those with established Alzheimer’s disease (AD).

ACE-Is were one of the first antihypertensives to be studied, particularly in AD, the most prevalent form of dementia. Patients with AD have abnormal cleavage of amyloid precursor protein resulting in a pathological accumulation of amyloid β (Aβ). The relationship between ACE and the accumulation of Aβ is complex and different polymorphisms have been postulated to either increase, or decrease, the risk of developing AD. ACE activity is increased in AD, proportional to the Aβ load. Centrally acting ACE-Is (CACE-Is) that cross the blood–brain barrier may have a greater impact than those that do not. The CACE-I perindopril, administered to mouse models, showed a significant protective effect and reversed CI more than did the non-centrally acting imidapril and enalapril. Patients receiving CACE-Is have a reduced rate of cognitive decline compared to both non-centrally acting ACE-Is and CCBs. The Cardiovascular Health Study demonstrated no reduced risk in the incidence of dementia in those taking CACE-Is compared to other classes of antihypertensives. Those prescribed CACE-Is had a reduced rate of cognitive decline and less impairment in instrumental activities of daily living compared to those taking non-centrally acting agents. Prescription of ARBs and ACE-Is is also associated with reduced incidence of both vascular dementia and mixed dementia subtypes.

Outside of clinical trials, there are few data on the effects of CACE-Is on the rate of cognitive decline in patients with dementia. Given this, and the growing evidence for antihypertensive agents, particularly CACE-Is, in reducing the incidence and rate of cognitive decline, we compared the rates of decline in patients taking CACE-Is (called CACE-I) with those not currently prescribed CACE-Is (called NoCACE-I), in those with established dementia, attending a memory clinic. We also examined whether patients started on CACE-Is while attending clinic (called NewCACE-I), behaved differently during their first 6 months of treatment, compared to the NoCACE-I group and those already established on CACE-Is.

METHODS

Data collection

Data were analysed from the Geriatric Assessment Tool (GAT) database, a customised software application that automates physicians’ clinic assessments. Data were collected in memory clinics in two university hospitals in Ontario, Canada. The database contains over 8000 individual assessments from 1749 people aged 41–104 years. GAT data, collected between 1999 and 2010, includes age, gender, education, medical diagnosis, BP, laboratory findings, medications, etc and the scores of two cognitive screening tests, the Standardised Mini-Mental State Examination (SMMSE) and the Quick Mild Cognitive Impairment (Qmci) screen, a new cognitive screen, more sensitive and specific for differentiating MCI from normal cognition and dementia than the SMMSE. Both tests were administered to patients by trained raters (clinic nurses) blind to the diagnosis, prior to each assessment, to monitor progression.

The Qmci has six subtests covering five cognitive domains: orientation, working memory, semantic memory (verbal fluency for animals), visual spatial (clock drawing) and two tests of episodic memory (delayed recall and immediate recall logical memory). It is scored out of 100 points.

Subjects

Patients with dementia were diagnosed by a consultant geriatrician using NINCDS and the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Only patients with AD, vascular or mixed dementias (Alzheimer’s/vascular) were included in this analysis. As there is little evidence that antihypertensive medications affect other dementia subtypes, patients with Parkinson’s disease dementia, fronto-temporal dementia, Lewy body dementia, alcohol-related dementia, post-trauma and post-anaesthetic dementia were excluded. Patients with MCI, n=235, defined as those with subjective and corroborated memory loss, without obvious loss of function, were...
excluded. Patients with MCI were excluded because few, n=12, had baseline and end-point Qmci scores available. Although the SMMSE was available, it is insensitive to MCI, and rates of cognitive decline vary, depending on the cognitive measures used. Patients with normal cognition, n=181 and depression, n=397 were also excluded. Participants were screened for depression using the 15-point Geriatric Depression Scale. As there is limited evidence that ACE-Is affect comorbid depression, while depression negatively affects the results of cognitive testing, 397 participants with depression were excluded: 260 with CI and comorbid depression and 137 with normal cognition and depression. Patients with depression were predominantly (63%) women and were significantly younger than patients without depression, mean age 72.7 (SD 10.7), p<0.001. Patients were also excluded if they did not have the results of either the Qnuci or SMMSE available at both the baseline and end point. Changes between the baseline and end-point (last visit) scores were standardised at 6 months to facilitate comparison between all groups. In total, 56% (n=456) of patients with dementia did not have the same cognitive test recorded at two visits and were therefore excluded. Regression analysis, adjusting for baseline characteristics (age, gender, education and BP) between participants without follow-up and those included, showed no significant difference in baseline SMMSE (p=0.06) or Qmci scores (p=0.51). Patient selection is presented graphically in figure 1. The CACE-I group included patients currently prescribed the following CACE-Is: perindopril, ramipril, trandolapril, captopril, fosinopril, lisinopril, prinivil and monopril.

Figure 1 Flow chart demonstrating the breakdown of the patients included in the Geriatric Assessment Tool (GAT) database.

Gao Y, O’Caoimh R, Healy L, et al. BMJ Open 2013;3:e002881. doi:10.1136/bmjopen-2013-002881
NoCACE-I included patients who were not currently receiving CACE-Is, irrespective of the BP readings, diagnosis of hypertension or whether they were receiving other antihypertensive medications.

Analysis

Our goal was to determine whether there were differences in rates of change, from the baseline to the end point (the time point when cognitive scores were last available), in Qmci and SMMSE scores between patients in the NoCACE-I, NoCACE-I and NewCACE-I groups while attending clinic. Given that regulatory authorities like the US Food and Drug Administration require evidence of change in cognitive tests over 6 months to confirm benefit from new medications, we used change scores from the baseline, on a six-monthly basis, according to the formula:

\[
\text{Rate of decline} = \frac{(\text{Baseline score} - \text{end point score})}{6/\text{duration in months}}
\]

We also used multivariate regression to compare end-point cognitive scores (SMMSE and Qmci), adjusted for the baseline cognitive scores and characteristics (age, years of education, duration of follow-up and BP), between the three groups (CACE-I, NoCACE-I and NewCACE-I). Data were analysed using SPSS V.18.0. The Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test for normality. Non-normally distributed data were compared with the Mann-Whitney U test. Categorical data were analysed with \( \chi^2 \) tests.

RESULTS

Baseline characteristics

In total, there were 817 patients with dementia. Of these, 361 with SMMSE and Qmci scores recorded at two or more visits were included for analysis, 85 receiving CACE-Is and 276 receiving NoCACE-Is. The mean age of those included was 77.9 years with an SD of 8.1 years. Half (50.3%) were men and the mean time spent in education was 11.2 years. The mean age of those included was 77.9 years with an SD of 8.1 years. Half (50.3%) were men and the mean time spent in education was 11.2 years. The mean age of those included was 77.9 years with an SD of 8.1 years. Half (50.3%) were men and the mean time spent in education was 11.2 years.

Results for the CACE-I, NoCACE-I and NewCACE-I groups were 0.8, 1.0 and 1.2, respectively, per 6 months. The median change in SMMSE scores between the baseline and end point for those included was 0.69 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months.

There was a small but non-significant difference in the SMMSE median rate of decline over 6 months for patients taking CACE-Is, compared to NoCACE-I patients, \( p=0.77 \). The difference in the median rates of decline in SMMSE scores between the baseline and end point for those included was 0.69 points per 6 months (IQR of 2). The median SMMSE score differences for the CACE-I, NoCACE-I and NewCACE-I groups were 0.8, 1.0 and 1.2, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months. For the Qmci, the median change was 2 points per 6 months, with median Qmci score differences for the CACE-I and NoCACE-I groups of 1.8 and 2.1, respectively, per 6 months.
The median decline in scores (rate per 6 months) for the NewCACE-I group, on the SMMSE, was −1.2 points for the NewCACE-I group, significantly less than for the CACE-I group (median 0.8); p=0.003 and NoCACE-I group (median 1.0), p=0.001. The Qmci could not be compared for the NewCACE-I group, as the numbers were too small. These results are presented in table 3. Multivariate regression analysis was used to compare the end-point cognitive scores (SMMSE and Qmci), adjusting for baseline cognitive scores (SMMSE and Qmci) and patient characteristics (age, education, duration of follow-up and BP). There were significant differences in end-point scores for the SMMSE (p=0.002) between all three groups (CACE-I, NoCACE-I and NewCACE-I). No significant difference was seen, for the Qmci, comparing the CACE-I and NoCACE-I groups, (p=0.172).

CONCLUSION
This study demonstrates a small reduction in the rate of cognitive decline, measured with the SMMSE and Qmci, in patients taking CACE-Is compared to the NoCACE-I group. The changes in Qmci scores over 6 months were small but statistically significant. The SMMSE scores, while non-significant, suggested a possible slower progression among those currently receiving CACE-Is. NewCACE-I patients, started on CACE-Is while attending clinic, showed a median improvement rather than a decline in SMMSE scores, over the first 6 months of treatment, compared to those already taking CACE-Is and those not currently treated with CACE-Is. These results confirm an association between the use of CACE-Is, particularly during the first 6 months of treatment, and a reduced rate of cognitive decline. This is the first study to demonstrate that cognitive scores improve in patients starting on CACE-Is, compared to those already established on maintenance treatment. This may have been related to better medication compliance, the effects of improved BP control or increased cerebrovascular perfusion after initial treatment.

The strength of the study lies in its large numbers and inclusion of different (AD, vascular and mixed) dementia subtypes. The study also investigates the effects of CACE-Is in an unselected clinic sample of older adults, whose mean age approached 80 years. It has a number of limitations. This study is an analysis of observational data collected in a ‘real world’ setting, where treatments, including antihypertensive agents, were administered on the basis of clinical judgement. Observational studies like this are subject to bias in that those who receive treatment may be systematically different from those who do not.

### Table 2 Baseline and end-point (last visit) SMMSE and Qmci scores

| Groups | Baseline age, mean (±SD) | Gender (male, %) | Duration of follow-up in months, median (Q3–Q1) | Baseline score, median (Q3–Q1) | End-point score, median (Q3–Q1) |
|--------|-------------------------|------------------|-----------------------------------------------|-------------------------------|---------------------------------|
| SMMSE  | CACE-I                  | 83 77.3 (±6.6)   | 53                                            | 17 (34–7)                     | 22 (25–19)                     | 20 (25–14)                     |
|        | NoCACE-I                | 270 77.1 (±7.6)  | 49.3                                          | 18 (31–9)                     | 23 (26–19)                     | 20 (25–13)                     |
|        | NewCACE-I               | 30 77.3 (±8.2)   | 50                                            | 6 (7–4)                       | 23 (27–18)                     | 24 (27–19)                     |
| Qmci   | CACE-I                  | 41 78.9 (±6.1)   | 56.1                                          | 16 (31–7)                     | 36 (44–23)                     | 29 (49–15)                     |
|        | NoCACE-I                | 114 78.0 (±7.6)  | 49.1                                          | 11 (24–6)                     | 38 (47–27)                     | 32 (45–17)                     |

CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.

### Table 3 Comparison of differences in Qmci and SMMSE scores between baseline and end point

| Groups            | Mann-Whitney U test (p Values) |
|-------------------|---------------------------------|
| Changes in Qmci   |                                 |
| CACE-I (53) vs NoCACE-I (102) | median = 1.8* vs median = 2.1* | 0.049 |
| CACE-I (113) vs NoCACE-I (240) | median = 0.8* vs median = 1.0* | 0.77 |
| NewCACE-I (30) vs NoCACE-I (240) | median = −1.2* vs median = 1.0* | 0.001 |
| NewCACE-I (30) vs CACE-I† (83) | median = −1.2* vs median = 0.8* | 0.003 |

Changes in SMMSE

| Groups            | Mann-Whitney U test (p Values) |
|-------------------|---------------------------------|
| Changes in SMMSE  |                                 |

†CACE-I group excluding NewCACE-I patients.

CACE-I, patients currently receiving ACE inhibitors; NewCACE-I, patients who were newly started on CACE-Is; NoCACE-I, patients who are not currently prescribed CACE-Is; Qmci, Quick Mild Cognitive Impairment; SMMSE, Standardised Mini-Mental State Examination.
who do not. That said, the baseline demographic characteristics of the groups were similar and few participants, in the NewCACE-I group, received other medications that could have accounted for the differences observed. Compliance with antihypertensive treatment, which has been shown to reduce with time,\(^{56,57}\) could also have been a confounding factor and may have accounted for the improvement in the NewCACE-I group. Similarly, duration of treatment with antihypertensive medications, prior to attending clinic, could not be established for the CACE-I and NoCACE-I groups in this retrospective analysis.

Although most patients in the database had a Qmci or SMMSE recorded, large numbers lacked results at the baseline or end point, limiting the numbers that could be included in the analysis. It is possible that the results would have differed with more complete data on all patients. However, the baseline cognitive scores were similar between those included and excluded because of missing data. In the comparison of the subgroup scores, change over the first 6 months of treatment was analysed as this is the accepted time scale to show evidence of benefit in clinical drug trials.\(^{53}\) Although a small percentage (9%) had a shorter interval between the baseline and end-point scores, the duration of follow-up was standardised at 6 months to facilitate comparison. The accepted standard for measuring cognitive change is the ADAS-cog.\(^{58}\) As this was an observational study in a clinic setting, only the Qmci and the commonly used SMMSE were available. The ADAS-cog is not an ideal test\(^{29}\) and the Qmci has been shown to be as sensitive to change as its standardised version, the SADAS-cog.\(^{60}\) Significant differences, between NewCACE-I and the other groups’ scores, using the SMMSE, could not be replicated with the Qmci, as the numbers were too small to analyse.

In summary, this study demonstrates an association between the use of CACE-Is and reduced rates of cognitive decline, in an unselected sample of clinic patients with dementia, particularly in the first 6 months of treatment. This supports the growing body of evidence for the use of ACE-Is and other antihypertensive agents in the management of dementia.\(^{16}\) Although the differences were small and of uncertain clinical significance, if sustained over years, the compounding effects may well have significant clinical benefits. However, this may be tempered by recent evidence suggesting that ACE-Is, by interfering with degradation of Aβ, could contribute to increased amyloid burden,\(^{61-65}\) potentially accelerating dementia severity and rates of cognitive decline.\(^{34}\) Indeed, ACE-Is may even increase mortality in patients with CI, suggesting that if ACE-Is are proven to be beneficial in dementia, not all patients will benefit.\(^{64}\) Further study with an appropriately powered randomised trial is needed to confirm these findings and determine if and for how long these effects are sustained.\(^{65}\) If these data can be reproduced in a randomised trial of sufficient length incorporating appropriate outcome measures, such as an amyloid positron emission tomography, then these agents are likely to have significant benefits in delaying or even preventing dementia.

**Author affiliations**

1. Centre for Gerontology and Rehabilitation, University College Cork, St Finbarr’s Hospital, Cork City, Ireland
2. Department of Business Information Systems, University College Cork, Cork, Ireland
3. Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland
4. Mercy University Hospital, Cork, Ireland
5. Clinical Research Facility, Mercy University Hospital, Cork, Ireland
6. Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada
7. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

**Contributors**

YG performed the data processing, statistical analysis and covrrote the paper with ROC. ROC also assisted with the submission of the manuscript. LH was responsible for performing the literature search and writing the introduction. DMK advised on the pharmacology of ACE inhibitors and contributed to writing the manuscript. JE and GG were involved in the data analysis plan, oversight of statistical analysis and preparation of the manuscript. DS gave input in statistical analysis and was the joint supervisor of YG. DWM contributed to collection of patient data, gave input in the preparation of the manuscript, and was the joint supervisor of YG and ROC. All authors have read and approved the final version of the manuscript.

**Funding**

The Centre for Gerontology and Rehabilitation is funded by Atlantic Philanthropies, the Health Services Executive Ireland, the Irish Hospice Foundation and the Canadian Institutes of Health Research.

**Competing interests** Not commissioned; externally peer reviewed.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**REFERENCES**

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. *Lancet* 2005;366:2112–17.
2. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000–2050: potential implication of treatment advances. *Annu Rev Public Health* 2002;23:213–31.
3. Whitmer R, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. *Neurology* 2005;64:277–81.
4. Breteler MMB, Claus JJ, Grobbee DE, et al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study. *BMJ* 1994;308:1604–8.
5. Rozzini L, Vicini Chiloi B, Trabucchi M, et al. Antihypertensive medications influence the rate of conversion from mild cognitive impairment to Alzheimer disease. *Arch Neurol* 2008;65:98–9.
6. Duron E, Rigaud AS, Dubail D, et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer’s disease. *Am J Hypertens* 2009;22:1020–4.
7. Ligthart SA, Van Charante EPM, Van Goor WA, et al. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. *Vasc Health Risk Manag* 2010;6:775.
8. Collaborative P, Neal B, MacMahon S. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. *Arch Intern Med* 2003;163:1069–75.
9. Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: the Canadian Study of Health and Aging. *Arch Neurol* 2010;67:187.
10. Tolleson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. *Biol Psychiatry* 1990;27:1133–42.
11. Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nifedipine in Alzheimer’s patients—an open-label trial. *Int J Geriatr Psychiatry* 2012;27:415–22.
12. Hajiar I, Brown L, Mack WJ, et al. Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol 2012;69:1632–8.

13. Li NG, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010;340:c5645.

14. Litthel H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86.

15. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004;63:1482–4.

16. Rizzoli L, Chilovi BV, Bortolletti E, et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2006;21:550–5.

17. Hajiar I, Hart M, Milberg W, et al. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr 2009;9:48.

18. Boon IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy 2008;28:366–75.

19. Staessen JA, Fagard R, Thijis L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757–64.

20. Forette F, Sexl MU, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046.

21. Maxwell CJ, Hogan DB, Eby EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ 1999;161:501–6.

22. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of the large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET/TRANSCEND) trials. Am Heart J 2004;148:52.

23. Mielke M, Rosenberg P, Tschanj J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69:1850–8.

24. Bellie KM, Pigeon JG, Stang PE, et al. Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 2004;18:208–13.

25. Rosenberg P, Mielke M, Tschanj J, et al. Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. Am J Geriatr Psychiatry 2008;16:883.

26. Brunström H, Gustafson L, Passant U, et al. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr 2009;49:146–9.

27. Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neuchem 2009;10:1129–34.

28. Kehoe PG, Russ C, McIlroy S, et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 1999;21:71.

29. Lehmann DJ, Cortina-Borja M, Marden DR, et al. Large meta-analysis evaluates the ACE insertion-deletion polymorphism as a marker of Alzheimer’s disease. Am J Epidemiol 2005;162:305–17.

30. Miners J, Ashby E, Van Helmond Z, et al. Angiotensin-converting enzyme (ACE) gene and activity in Alzheimer’s disease, and relationship of p12 isoform ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurol Biol 2007;34:181–93.

31. Dong YF, Kataoka K, Tokutomi Y, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J 2011;25:2911–20.

32. Yamada K, Uchida S, Takahashi S, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res 2010;1352:176–82.

33. Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: design and rationale. Ann Epidemiol 1991;1:263–76.

34. Sink KM, Leng X, Williamson J, et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009;169:1195.

35. Hanes DS, Weir MR. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. Am J Geriatr Cardiol 2007;16:175–82.

36. Davies NM, Kehoe PG, Ben-Shlomo Y, et al. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis 2011;26:699–708.

37. Molloy DW, Alemayehu E, Roberts R. Reliability of a standardized mini-mental state examination compared with the traditional mini-mental state examination. Am J Psychiatry 2001;158:148–52.

38. Molloy DW, Standish TM. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 1997;9:87–94.

39. O’Coirin R, Gao Y, McGlade C, et al. Comparison of the quick mild cognitive impairment (Qmci) screen and the MMSE in screening for mild cognitive impairment. Age Ageing 2012;41:624–8.

40. O’Coirin R, Gao Y, Gallagher PF, et al. Which part of the quick mild cognitive impairment screen (Qmci) discriminates between normal cognition, mild cognitive impairment and dementia? Age Ageing 2013;42:324–30.

41. Mischoulon D, Greden J, Foltstein M, et al. Clinical diagnosis of Alzheimer’s disease report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;4;399–44.

42. First M. Diagnostic and statistical manual of mental disorders. DSM IV. edn APA 1994:97.

43. Louis ED, Benito-León J, Bermejo-Pareja F. Antihypertensive agents and risk of Parkinson’s disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology 2005;32:286–92.

44. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 2007;69:1688–95.

45. Ross S, Landweer E, Houterman M, et al. Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 2003;74:1574–5.

46. Londos E, Passant U, Gustafson L. Blood pressure and drug treatment in clinically diagnosed Lewy body dementia and Alzheimer’s disease. Arch Gerontol Geriatr 2000;30:30–46.

47. Portel F, Ousset P, Vissier P, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003;74:1574–5.

48. Monsell SE, Liu D, Weintraub S, et al. Comparing measures of decline to dementia in amnestic MCI subjects in the National Alzheimer’s Coordinating Center’s (NACC) Uniform Data Set. Int Psychogeriatr 2012;24:155S.

49. Yesavage J, Guralnik J. Geriatric Depression Scale. Psychopharmac Bull 1988;24:709.

50. Rogers D, Pies R. General medical drugs associated with depression. Psychiatry (Edgmont) 2008;3:28.

51. Porter RJ, Gallagher P, Thompson JM, et al. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry 2003;182:214–20.

52. Solfrizzi V, Scalfato E, Frisardi V, et al. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Aging (Dordr) 2013(2):441–53.

53. Matthews HP, Korhey J, Wilkinson DG, et al. Dementia in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 2000;15:713–20.

54. Hatazawa J, Shimosegawa E, Osaki Y, et al. Long-term angiotensin-converting enzyme inhibitor perindopril therapy improves cerebral perfusion reserve in patients with previous minor stroke. Stroke 2004;35:2117–22.

55. Lipsitz LA, Gagnon M, Vyas M, et al. Angihypertensive therapy increases cerebral blood flow and carotid distensibility in hypertensive elderly subjects. Hypertension 2005;45:216–21.

56. Chapman RH, Benner JS, Petrella AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147.

57. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999–2010.

58. Rosen WG, Moos RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984.
Centrally acting ACE inhibitors in dementia

59. Connor DJ, Sabbagh MN. Administration and scoring variance on the ADAS-Cog. *J Alzheimers Dis* 2008;15:461–4.

60. O’Caoimh R, Svendrovski A, Johnston B, *et al.* Comparison of the Qmcl to the SADAS-Cog. *J Clin Epidemiol* 2013. In press.

61. Hu J, Igarashi A, Kamata M, *et al.* Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. *J Biol Chem* 2001;276:47863–8.

62. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer’s disease: current standing of the angiotensin hypothesis? *J Alzheimers Dis* 2012;30:S251–68.

63. Fournier A, Oprisiu-Fournier R, Serot J-M, *et al.* Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. *Expert Rev Neurother* 2009;9:1413–31.

64. Kehoe PG, Davies NM, Martin RM, *et al.* Associations of angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. *J Alzheimers Dis* 2013;33:999–1008.

65. Todd S, McGuinness B, Passmore AP. Designing appropriate clinical trials to assess ACEI use and cognitive decline in older adults with hypertension. *Arch Intern Med* 2010;170:107.